Levetiracetam

CHEMBL1286 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

170.2 g/mol

LogP

-0.3

Phase

4

An anticonvulsant used to treat focal and generalized seizures in epilepsy, and studied for mood stabilization in bipolar disorder. It works through a unique mechanism involving synaptic vesicle protein 2A (SV2A) to reduce abnormal neuronal activity.

Masse moléculaire

170,2100 g/mol

LogP

-0,30

TPSA

63,40 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Multiple Sclerosis Stroke Lymphoma Chronic Pain Malaria Leukemia

Mécanisme d'action

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@@H](C(N)=O)N1CCCC1=O

InChI

InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

Molecular Formula

C8H14N2O2

HBD / HBA

1 / 2

Liaisons Rotatives

3

Atomes Lourds

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An anticonvulsant used to treat focal and generalized seizures in epilepsy, and studied for mood stabilization in bipolar disorder. It works through a unique mechanism involving synaptic vesicle protein 2A (SV2A) to reduce abnormal neuronal activity.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Levetiracetam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1286. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5284583. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Levetiracetam sur PillFYI

Structure

Données Clés

Formule: C8H14N2O2
Synonymes: 10

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.